Renal fibrosis is a hallmark of chronic kidney disease, while efficient therapy against renal fibrosis is still lacking. In this study, we investigated the role of a novel small-molecule compound VCP979 on renal fibrosis and inflammation in a rat model of unilateral ureteral obstruction (UUO). One week after the UUO surgery, rats were administered VCP979 by gavage for one week, and after treatment, magnetic resonance imaging of T1rho mapping and histopathological analysis were performed to evaluate renal fibrosis in vivo and ex vivo. This study showed that treatment with VCP979 effectively reduced renal fibrosis, extracellular matrix accumulation, and alleviated epithelial–mesenchymal transition in UUO rats, as well as improved renal function. In vivo T1rho mapping displayed increased T1rho values in the UUO rats, which was decreased after VCP979 treatment, and a positive correlation was detected between the T1rho values and the percentage of fibrotic area. Moreover, the administration of VCP979 also ameliorated the inflammatory cytokines expression and the infiltration of macrophages in renal tissues. Mechanistically, VCP979 treatment inhibited the activation of p38 mitogen–activated protein kinase, nuclear factor-kappa B, and transforming growth factor-β1/Smads signaling pathways. These results indicated that VCP979 could be an effective therapeutic agent for alleviating renal fibrosis and inflammation in the rat model of UUO via its antifibrotic and anti-inflammatory effects.
KuppeCIbrahimMMKranzJZhangXZieglerSPerales-PatónJJansenJReimerKCSmithJRDobieRWilson-KanamoriJRHalderMXuYKabganiNKaeslerNKlausMGernholdLPuellesVGHuberTBBoorPMenzelSHoogenboezemRMBindelsEMJSteffensJFloegeJSchneiderRKSaez-RodriguezJHendersonNCKramannR.Decoding myofibroblast origins in human kidney fibrosis.Nature2021;589:281–6
4.
ArkinMRWellsJA.Small-molecule inhibitors of protein-protein interactions: progressing towards the dream.Nat Rev Drug Discov2004;3:301–17
5.
StambeCAtkinsRCTeschGHMasakiTSchreinerGFNikolic-PatersonDJ.The role of p38alpha mitogen-activated protein kinase activation in renal fibrosis.J Am Soc Nephrol2004;15:370–9
6.
FurukawaFMatsuzakiKMoriSTahashiYYoshidaKSuganoYYamagataHMatsushitaMSekiTInagakiYNishizawaMFujisawaJInoueK.P38 MAPK mediates fibrogenic signal through Smad3 phosphorylation in rat myofibroblasts.Hepatology2003;38:879–89
7.
DenhezBRousseauMDancosstDALizotteFGuayAAuger-MessierMCôtéAMGeraldesP.Diabetes-induced DUSP4 reduction promotes podocyte dysfunction and progression of diabetic nephropathy.Diabetes2019;68:1026–39
8.
WangDWarnerGMYinPKnudsenBEChengJButtersKALienKRGrayCEGarovicVDLermanLOTextorSCNathKASimariRDGrandeJP.Inhibition of p38 MAPK attenuates renal atrophy and fibrosis in a murine renal artery stenosis model.Am J Physiol Renal Physiol2013;304:F938–47
9.
MengXMNikolic-PatersonDJLanHY.TGF-beta: the master regulator of fibrosis.Nat Rev Nephrol2016;12:325–38
10.
ZhaoXKwanJYYYipKLiuPPLiuFF.Targeting metabolic dysregulation for fibrosis therapy.Nat Rev Drug Discov2020;19:57–75
11.
GuYYLiuXSHuangXRYuXQLanHY.TGF-β in renal fibrosis: triumphs and challenges.Future Med Chem2020;12:853–66
12.
ShahNGTulapurkarMERamarathnamABrophyAMartinezRIIIHomKHodgesTSamadaniRSinghISMacKerellADShapiroPHasdayJD.Novel noncatalytic substrate-selective p38alpha-specific MAPK inhibitors with endothelial-stabilizing and anti-inflammatory activity.J Immunol2017;198:3296–306
13.
LiuJMengQLiangXZhuangRYuanDGeXCaoHLinFGongXFanHWangBZhouXLiuZ.A novel small molecule compound VCP979 improves ventricular remodeling in murine models of myocardial ischemia/reperfusion injury.Int J Mol Med2020;45:353–64
14.
XuTDingJGeHXuXScammellsPWangBJuS.Effects of VCP979 novel p38 mitogen activated protein kinase inhibitor on progression of pancreatic cancer in mouse model with diabetic conditions.J Biomed Nanotechnol2019;15:1325–33
15.
CaiYLuCXuTMaYMinSScammellsPWangBJuS.Diffusion tensor imaging evaluation of axonal/white matter remodeling in a mouse model of diabetic stroke treated with novel p38 MAPK inhibitor, VCP979.J Biomed Nanotechnol2018;14:585–93
16.
JiangKFergusonCMLermanLO.Noninvasive assessment of renal fibrosis by magnetic resonance imaging and ultrasound techniques.Transl Res2019;209:105–20
17.
WhittierWLKorbetSM.Timing of complications in percutaneous renal biopsy.J Am Soc Nephrol2004;15:142–7
18.
CapretzTPatelRMOkhunovZ.Percutaneous renal biopsy: approach, diagnostic accuracy and risks.Curr Opin Urol2018;28:369–74
19.
HuGLiangWWuMLaiCMeiYLiYXuJLuoLQuanX.Comparison of T1 mapping and T1rho values with conventional diffusion-weighted imaging to assess fibrosis in a rat model of unilateral ureteral obstruction.Acad Radiol2019;26:22–9
20.
ThompsonEWKamesh IyerSSolomonMPLiZZhangQPiechnikSWerysKSwagoSMoonBFRodgersZBHallAKumarRRezaNKimJJamilADesjardinsBLittHOwensAWitscheyWRTHanY.Endogenous T1ρ cardiovascular magnetic resonance in hypertrophic cardiomyopathy.J Cardiovasc Magn Reson2021;23:120
21.
MorrellGRZhangJLLeeVS.Magnetic resonance imaging of the fibrotic kidney.J Am Soc Nephrol2017;28:2564–70
22.
ZouLJiangJZhangHZhongWXiaoMXinSWangYXingW.Comparing and combining MRE, T1ρ, SWI, IVIM, and DCE-MRI for the staging of liver fibrosis in rabbits: assessment of a predictive model based on multiparametric MRI.Magn Reson Med2022;87:2424–35
23.
van OorschotJWGucluFde JongSChamuleauSALuijtenPRLeinerTZwanenburgJJ.Endogenous assessment of diffuse myocardial fibrosis in patients with T1rho-mapping.J Magn Reson Imaging2017;45:132–8
24.
HectorsSJBaneOKennedyPEl SalemFMenonMSegallMKhaimRDelaneyVLewisSTaouliB.T1ρ mapping for assessment of renal allograft fibrosis.J Magn Reson Imaging2019;50:1085–91
25.
WangFOtsukaTTakahashiKNaruiCColvinDCHarrisRCTakahashiTGoreJC.Renal tubular dilation and fibrosis after unilateral ureter obstruction revealed by relaxometry and spin-lock exchange MRI.NMR Biomed2021;34:e4539
26.
Percie du SertNHurstVAhluwaliaAAlamSAveyMTBakerMBrowneWJClarkACuthillICDirnaglUEmersonMGarnerPHolgateSTHowellsDWKarpNALazicSELidsterKMacCallumCJMacleodMPearlEJPetersenOHRawleFReynoldsPRooneyKSenaESSilberbergSDStecklerT.The ARRIVE guidelines 2.0: updated guidelines for reporting animal research.BMJ Open Sci2020;4:e100115
27.
OkaMSekiyaSSakiyamaRShimizuTNittaK.Hepatocyte growth factor-secreting mesothelial cell sheets suppress progressive fibrosis in a rat model of CKD.J Am Soc Nephrol2019;30:261–76
28.
ChangDWangYCXuTTPengXGCaiYWangLBaiYYJuS.Noninvasive identification of renal hypoxia in experimental myocardial infarctions of different sizes by using BOLD MR imaging in a mouse model.Radiology2018;286:129–39
29.
ChangXZhenXLiuJRenXHuZZhouZZhuFDingKNieJ.The antihelmenthic phosphate niclosamide impedes renal fibrosis by inhibiting homeodomain-interacting protein kinase 2 expression.Kidney Int2017;92:612–24
30.
LiRGuoYZhangYZhangXZhuLYanT.Salidroside ameliorates renal interstitial fibrosis by inhibiting the TLR4/NF-kappaB and MAPK signaling pathways.Int J Mol Sci2019;20:1103
31.
ChungACZhangHKongYZTanJJHuangXRKoppJBLanHY.Advanced glycation end-products induce tubular CTGF via TGF-beta-independent Smad3 signaling.J Am Soc Nephrol2010;21:249–60
32.
DjudjajSBoorP.Cellular and molecular mechanisms of kidney fibrosis.Mol Aspects Med2019;65:16–36
33.
BreyerMDSusztakK.The next generation of therapeutics for chronic kidney disease.Nat Rev Drug Discov2016;15:568–88
34.
LiXPanJLiHLiGLiuXLiuBHeZPengZZhangHLiYXiangXChaiXYuanYZhengPLiuFZhangD.DsbA-L mediated renal tubulointerstitial fibrosis in UUO mice.Nat Commun2020;11:4467
35.
Rayego-MateosSValdivielsoJM.New therapeutic targets in chronic kidney disease progression and renal fibrosis.Expert Opin Ther Targets2020;24:655–70
36.
GipsonDSHladunewichMALafayetteRSedorJRRovinBHBarbourSJMcMahonAJennetteJCNachmanPHWilletteRNPaglioneMGaoFRoss TerresJAVallowSHollandMCThorneloeKSSprecherDL.Assessing the impact of losmapimod on proteinuria in idiopathic focal segmental glomerulosclerosis.Kidney Int Rep2020;5:1228–39
37.
O’DonoghueMLGlaserRAylwardPECavenderMACrispAFoxKALawsILopez-SendonJLStegPGTherouxPSabatineMSMorrowDA.Rationale and design of the losmapimod to inhibit p38 MAP kinase as a therapeutic target and modify outcomes after an acute coronary syndrome trial.Am Heart J2015;169:622–30.e6
38.
GoldmanJWRosenLSTolcherAWPapadopoulosKBeeramMShiPPitouCBellRKulanthaivelPZhangXFinkAChanEMShahirAFarringtonDPatnaikA.Phase 1 and pharmacokinetic study of LY3007113, a p38 MAPK inhibitor, in patients with advanced cancer.Invest New Drugs2018;36:629–37
39.
ZhouJZhongJHuangZLiaoMLinSChenJChenH.TAK1 mediates apoptosis via p38 involve in ischemia-induced renal fibrosis.Artif Cells Nanomed Biotechnol2018;46:1016–25
40.
O’KeefeSJMudgettJSCupoSParsonsJNChartrainNAFitzgeraldCChenSLLowitzKRasaCViscoDLuellSCarballo-JaneEOwensKZallerDM.Chemical genetics define the roles of p38alpha and p38beta in acute and chronic inflammation.J Biol Chem2007;282:34663–71
41.
GuoYXiaoYZhuHGuoHZhouYShentuYZhengCChenCBaiY.Inhibition of proliferation-linked signaling cascades with atractylenolide I reduces myofibroblastic phenotype and renal fibrosis.Biochem Pharmacol2021;183:114344
42.
AmosLAMaFYTeschGHLilesJTBreckenridgeDGNikolic-PatersonDJHanY.ASK1 inhibitor treatment suppresses p38/JNK signalling with reduced kidney inflammation and fibrosis in rat crescentic glomerulonephritis.J Cell Mol Med2018;22:4522–33
43.
MackM.Inflammation and fibrosis.Matrix Biol2018;68–9:106–21
44.
LiaoYTanRZLiJCLiuTTZhongXYanYYangJKLinXFanJMWangL.Isoliquiritigenin attenuates UUO-induced renal inflammation and fibrosis by inhibiting Mincle/Syk/NF-Kappa B signaling pathway.Drug Des Devel Ther2020;14:1455–68
45.
LiQLiuBCLvLLMaKLZhangXLPhillipsAO.Monocytes induce proximal tubular epithelial-mesenchymal transition through NF-kappa B dependent upregulation of ICAM-1.J Cell Biochem2011;112:1585–92
46.
HuGLiangWWuMLaiCMeiYLiYXuJLuoLQuanX.Comparison of T1 mapping and T1ρ values with conventional diffusion-weighted imaging to assess fibrosis in a rat model of unilateral ureteral obstruction.Acad Radiol2019;26:22–9
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
